‘Active targeting’ enhances selectivity by functionalizing NPs with ligands (e.g., antibodies, peptides, aptamers) that bind tumor-specific receptors, such as HER2 or folate receptors in BC [279]. This evidence concerns the gene ERBB2 and neoplasm.